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ABSTRACT 
 
RNA interference (RNAi) is an evolutionary conserved gene silencing mechanism in which small interfering 
RNA (siRNA) mediates the sequence specific degradation of mRNA. The recent discovery that exogenously 
delivered siRNA can trigger RNAi in mammalian cells raises the possibility to use this technology as a 
therapeutic tool against pathogenic viruses. Indeed, it has been shown that siRNAs can be used effectively to 
inhibit virus replication. The focus of this review is on RNA interference strategies against HIV-1 and how 
this new technology may be developed into a new successful therapy. One of the hallmarks of RNAi, its se-
quence specificity, also presents a way out for the virus, as single nucleotide substitutions in the target region 
can abolish the suppression. Strategies to prevent the emergence of resistant viruses have been suggested and 
involve the targeting of conserved sequences and the simultaneous use of multiple siRNAs, similar to current 
highly active antiretroviral therapy. We present an additional strategy aimed at preventing viral escape by 
using a second generation of siRNAs that recognize the mutated target sites. 
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INTRODUCTION 
 
Highly-active antiretroviral therapy (HAART), which in-
volves the use of multiple antiviral agents, has been very 
successful in reducing the rates  of  progression to AIDS 
and death in people with HIV-1. However, adverse effects 
of the long-term use of these drug regimens, like toxicity 
and the emergence of drug resistant variants, obviate the 
need for new and improved methods to suppress HIV-1 in 
infected individuals. Recently, it was shown that delivery 
of siRNAs in mammalian cells can trigger a highly spe-
cific RNA interference response resulting in knockdown 
of the gene of interest. This finding raised the possibility 
that  RNA interference can  be used as a potent antiviral 
tool against HIV-1. 
 
siRNAs targeting HIV-1 sequences can inhibit virus pro-
duction and virus replication in transient transfection ex-
periments (Capodici et al, 2002; Coburn and Cullen, 2002; 
Hu et al, 2002; Jacque et al, 2002; Lee et al, 2003; Park et 
al, 2003; Dave and Pomerantz, 2004). The transient nature 
of these methods is not desirable in a therapeutic setting 
dealing with a persistent viral infection. Although patients 
may be treated with a stabilized form of siRNAs, the risk 
of  acquiring  resistant  HIV-1  mutants  is  relatively  high 
because the concentration of siRNAs will vary in different 
body  compartments.  Furthermore,  delivery  and  toxicity 
remain  major  issues  for  a  treatment  with  synthetic 
siRNAs. In contrast, if patients are treated with a stably 
integrated viral vector expressing a steady supply of inter-
fering  RNAs,  HIV-1  replication  will  be  inhibited  con-
stantly.  siRNAs  can  be  expressed  from  polymerase-III 
transcription units. The sense and anti-sense strands can be 
expressed from two different promoters, and RNAi is trig-
gered upon annealing of the two strands (Lee et al, 2002; 
Banerjea et al, 2003; Tran et al, 2003). More potent inhibi-
tion  was  achieved  when  the  sense  and  antisense  strand 
were expressed as a single transcript with the ability  to  
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from  a  duplex  hairpin  structure  (Brummelkamp  et  al, 
2002). HIV-1 replication can be effectively inhibited with 
such  short  hairpin  RNAs  (shRNA)  in  stably  transduced 
cell lines (Boden et al, 2003a; Unwalla et al, 2004; Das et 
al, 2004; Boden et al, 2004a; Lee et al, 2005).  
 
Because RNAi is highly sequence specific, a single point 
mutation can potentially result in full resistance to RNAi. 
Indeed, resistant variants can emerge when a single anti-
viral  shRNA  is  used  (Boden  et  al,  2003a;  Das  et  al, 
2004). The emergence of RNAi-resistant mutants poses a 
challenge for the development of RNAi based treatments 
for HIV-1 infected individuals. It has been suggested to 
use  multiple  highly-effective  shRNAs  that  target  con-
served  regions  of  the  viral  genome  (Berkhout,  2004). 
More potent suppression will further reduce the ability of 
the  virus  to  evolve,  and  escape  from  multiple  shRNA 
inhibitors will require several mutations. In this report, 
we will present an overview of current publications on 
RNAi against HIV-1. Furthermore, we have analyzed all 
published  HIV-1  targets  and present an outline  for  the 
effective use of RNAi against HIV. This includes a new 
strategy to prevent the emergence of resistant variants by 
including additional shRNAs that are directed against the 
most likely escape mutants. 
 
HIV-1 escapes from a single shRNA 
Two recent studies addressed the potency and durability 
of  anti-HIV  RNAi  approaches.  A  short  hairpin  RNA 
(shRNA) against the tat gene was expressed from an H1-
promoter in an adeno-associated virus vector (Boden et 
al,  2003a).  Potent  inhibition  of  HIV-1  replication  was 
scored, but an escape virus appeared in prolonged cul-
tures. Similar results were described for a shRNA against 
the Nef gene using a retroviral vector (Das et al, 2004). 
The latter study described 7 independent HIV-1 escape 
variants.  These  studies  convincingly  demonstrate  that 
inhibition is potent and sequence-specific, but also that 
HIV-1 is able to escape from the inhibitory action of a 
single shRNA. Boden et al described a single escape vi-
rus with a point mutation in the target sequence, and Das 
et al (2004) described a multitude of escape routes (point 
mutation, double point mutation, partial or complete de-
letion  of  the  target  sequence).  The  possibility  of  virus 
escape seems even more apparent with the recent demon-
stration that HIV-1 can also gain resistance by a point 
mutation outside the target sequence (Westerhout et al, 
2005). This mutation was demonstrated to change local 
RNA folding, such that the target sequence becomes in-
accessible  to  the  RNAi  machinery.  The  emergence  of 
resistant virus variants poses a serious problem for using 
RNA interference in a therapeutic setting. 
 
Counteracting viral escape with multiple shRNAs 
One strategy to counteract viral escape is to use multiple 
shRNAs  targeting  different  conserved  regions  of  HIV-1 
(Haasnoot  et  al,  2003;  Stevenson,  2003;  Hannon  and 
Rossi, 2004; Berkhout, 2004; Shankar et al, 2005). Con-
served targets in the HIV-1 RNA genome will not allow 
for  a  deletion-based  escape  route,  as  occurred  with  the 
shRNA  targeting  the  non-essential  Nef  gene  sequences 
(Das et al, 2004). One can try to estimate the chance of 
escape with one versus multiple shRNAs. First, we make 
the assumption that deletion is not an option for the virus; 
only point mutations are allowed to occur. In principle, a 
single  point  mutation  can  make the  virus  insensitive  to 
RNAi. The error rate of the reverse transcriptase of HIV-1 
is 3 x 10
-5 (Mansky, 1996), consequently the chance of 
viral escape for a 19 nucleotide target in a single infection 
is 19 x (3 x 10
-5) = 5.7 x 10
-4. Studies in the field of drug 
resistance indicate that an untreated HIV infected individ-
ual has a virus population size of 10
4 to 10
5. This means 
that for each shRNA, several potential escape variants are 
already  present  before  the  start  of  therapy.  Thus,  the 
emergence  of  a  drug  resistant  variant  seems  inevitable 
when  a  single  shRNA  is  used. When  multiple  shRNAs 
(N) are used simultaneously, the likelihood of obtaining a 
drug resistant variant drops exponentially with the num-
ber of shRNAs (5.7 x 10
-4)
N. If we assume that there is 
already resistance to at least one of the shRNAs used in a 
patient, than the chance of a resistant variant emerging is 
(5.7 x 10
-4)
N-1. For instance, if four shRNAs are used si-
multaneously,  the  chance  of  escape  is  1.9  x  10
-10.  Al-
though this chance seems remote given the average viral 
load in a patient, it cannot be excluded that multi-shRNA 
resistant mutants can evolve through recombination. 
 
That resistance can evolve, even after prolonged in vitro 
culturing, indicates that suppression of HIV-1 replication 
is not absolute when a single shRNA is used. Recently, it 
was  shown  that  inhibition  of  a  target  gene  is  increased 
proportionate to the shRNA expression level. This result 
was obtained by combining multiple expression cassettes 
encoding the same shRNA in a single vector (Gonzalez et 
al,  2005).  In  addition,  the  combination  of  two  different 
shRNAs resulted in effective and simultaneous inhibition 
of two targets, while their individual activity was main-
tained (Anderson et al, 2003; Schubert et al, 2005a). These 
results  indicate  that,  when  a  multiple  shRNA  strategy 
would be used against HIV-1, the magnitude of inhibition 
will  increase,  perhaps  approaching  complete  inhibition, 
combined with a severely reduced chance of escape.  
 
Target site selection 
During  the  HIV-1  life  cycle,  there  are  several  steps  at 
which  RNA  interference  may  inhibit  replication  (Figure 
1A). Upon virus infection, the incoming RNA genome is a 
potential target. There is controversy with regards to tar-
geting of the incoming HIV-1 genome with RNAi. Several 
publications  report  RNAi-mediated  degradation  of  the 
RNA  genome  during  infection  in  cells  transfected  with 
siRNAs (Capodici et al, 2002; Coburn and Cullen, 2002; 
Jacque et al, 2002), while others reported no effect at all 
(Surabhi and Gaynor, 2002; Hu et al, 2002). These contra-
dicting results may perhaps be explained by differences in 
target accessibility  in the context  of  the packaged RNA 
genome, since viral and/or cellular proteins may  protect 
some regions, but not all. Variations in experimental con-
ditions, e.g., the cell types used, differences in transfection 
efficiency, variable amounts of siRNAs or infectious HIV-
1 virus used, may also have caused these differences. Re-
cently, it was shown that cells expressing shRNAs from an 
integrated lentiviral vector effectively blocked integration 
of the DNA provirus at low multiplicity of infection; this 
effect was overcome with a high dose of virus (Joshi et al, 
2005). This result shows, in a relevant gene therapy setting,  
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Figure 1. The HIV-1 life cycle and possible opportunities for RNAi-mediated intervention. (A) After virus infection, the HIV-1 core 
with the RNA genome will be released into the cytoplasm. The incoming RNA genome represents a desirable target, since destruc-
tion of the genome (route 1) prevents reverse transcription and integration of the provirus. After integration of the provirus, viral 
messenger RNAs are expressed. Viral mRNAs can potentially be degraded in the nucleus (route 2) or in the cytoplasm (route 3), 
preventing viral protein production and virus particle assembly and release. (B) The proviral DNA genome. Early gene expression 
results in fully spliced mRNAs encoding for Tat, Rev and Nef. Late gene expression results in partially spliced mRNAs, encoding for 
Env, Vif, Vpr, and unspliced mRNA for Gag and Gag-Pol proteins or as the genomic RNA. 
 
 
 
that the incoming HIV-1 genome can be subject to RNAi-
mediated degradation. 
 
Late  in  infection,  viral  mRNAs  are  transcribed  from  the 
integrated provirus. The early viral transcripts are processed, 
resulting predominantly in spliced transcripts in the cyto-
plasm  (Figure  1B). Once  sufficient  Rev  protein  is  made, 
partially  spliced  messengers  and  unspliced  genomic  tran-
scripts will be exported out of the nucleus into the cyto-
plasm. It is generally believed that RNA interference is a 
cytoplasmic  phenomenon  (Meister  and  Tuschl,  2004; 
Shankar et al, 2005). Since it may be beneficial to block 
early viral gene expression, one may prefer HIV-1 target 
sequences that are present in (all) early transcripts (Purcell 
and Martin, 1993). For instance, down-regulation of Tat and 
Rev protein expression may block virus production early on. 
In the absence of Tat protein, no induction of the viral LTR 
promoter  occurs  and  without  Rev  the  shift  towards 
unspliced RNA cannot be made. In contrast, targeting se-
quences present exclusively in late unspliced mRNAs will 
allow for the production of early spliced mRNAs and early 
viral proteins. 
 
It has been shown that siRNAs targeting early transcripts 
down-regulate  all  transcripts  after  infection  with  HIV-1 
(Coburn  and  Cullen, 2002;  Lee et  al,  2003).  Contrary  to 
expectation, an siRNA targeting a gag sequence that is ex-
clusively present in unspliced, late mRNA gave a similar 
result (Novina et al, 2002). Although this result may reflect 
the combined effect of the destruction of the incoming ge-
nome and the targeting of viral messengers, it may also hint 
at the possibility that viral transcripts are cleaved by RNAi 
in the nucleus prior to splicing. This option was previously 
discarded  because  RNAi was considered  to  be  an  exclu-
sively cytoplasmic event (Novina et al, 2002). Supporting 
the  concept  of  nuclear  targeting  of  HIV-1  mRNAs,  both 
nuclear and cytoplasmic viral RNA was downregulated by a 
lentiviral shRNA against the late vpu transcript (Chang et al, 
2005).  It  was  recently  shown  that  RNA  interference  can 
effectively degrade mRNAs that are localized in the nucleus 
of mammalian cells (Robb et al, 2005). Similar results were 
obtained  with  shRNAs  delivered  by  a  lentiviral  vector 
(Langlois et al, 2005). These studies suggest that RNAi may 
also  occur in the nucleus, thus explaining the results ob-
tained with siRNAs that target late viral transcripts. 
 
In addition to the degradation of RNA, which is the focal 
point of this review, two other functions of RNA interfer-
ence may also contribute to inhibition of HIV-1 replication. 
First, the RNA interference silencing complex may silence 
mRNA translation. This process is less sensitive to sequence 
variation since perfect basepairing of siRNA and mRNA is 
not required. Second, inhibition can also occur through tran-
scriptional silencing mediated through chromatin remodel-
ing (Morris et al, 2004; Kawasaki and Taira, 2005). This 
would  prevent  the  expression  of  viral  transcripts.  It  was 
recently shown that targeting of the HIV-1 LTR promoter 
region results in sustained inhibition (Suzuki et al, 2005). 
Interestingly, methylation of CpG motifs was observed in 
and surrounding the siRNA target regions, implicating that 
transcriptional silencing suppressed HIV-1 replication. 
 
Since there is support for shRNA induced targeting of the 
incoming viral RNA genome and also suggestive evidence 
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that viral mRNAs may be degraded prior to splicing in the 
nucleus,  we  propose  that  target  sites  can  be  chosen 
throughout the HIV-1 genome. Selection can therefore be 
based solely on conservedness of the target sequence in 
different HIV-1 isolates. We have listed all 42 published 
siRNAs and shRNAs that were successfully used to inhibit 
HIV-1 production or replication (Table 1). It is important 
to note that each study used different ways to score inhibi-
tion of HIV-1 production, and in a few cases HIV-1 repli-
cation, such that a direct comparison is not possible. There 
is ample evidence that effective siRNAs against HIV-1 can 
be transformed into effective shRNAs (Coburn and Cullen, 
2002; Jacque et al, 2002; Han et al, 2004; Das et al, 2004; 
Nishitsuji et al, 2004; Boden et al, 2004a; Lee et al, 2005). 
We aligned all 42 RNAi target sequences with 538 HIV-1 
full  genome  sequences  available  from  the  Los  Alamos 
National  Laboratory  database using  the  PrimaAlign  tool 
available from their website (http://www.hiv.lanl.gov). We 
calculated the percentage of viral isolates that show com-
plete similarity to the published target sequence (Table 1). 
Nine of the 42 target sequences are conserved in at least 
half of known isolates, which represent the best candidates 
for the multiple shRNA approach.  
 
Counteracting  viral  escape  with  a  2
nd  generation  of 
shRNAs 
Although, the Nef gene target (Jacque et al, 2002; Das et 
al, 2004) is not highly conserved (Table 1) and, therefore, 
not perfectly suited for an RNAi based therapy, the exten-
sive set of viral escape variants described  for this RNAi 
treatment (Das et al, 2004) provided us with a tool to test a 
different strategy to prevent viral escape. The novel ap-
proach is to include a second generation of shRNAs that 
target  the  most  likely  escape  variants  (Figure  2A).  We 
constructed pSUPER vectors (Brummelkamp et al, 2002) 
expressing shRNAs directed against the mutated Nef se-
quences of the escape viruses (Figure 2B). HIV-1 molecu-
lar clones, based on pLAI (Peden et al, 1991), with one or 
two nucleotide substitutions in the target (Figure 2B), were 
co-transfected with a control pSUPER shLUC vector (Fig-
ure 2C, black bars) and relative virus production, as meas-
ured by Gag  CA-p24 production, was set at 100%. Co-
transfection of these molecular clones with the shNEF-wt 
plasmid showed strong inhibition of wild-type pLAI, but 
not of the variants with a mutated target site, thus confirm-
ing  the  sequence  specificity  of  RNAi  (Figure  2C,  grey 
bars). All pLAI variants, except the wild-type, were co-
transfected with the matching shRNA (Figure 2C, white 
bars). The R3 and R3’ escape mutants are potently inhib-
ited by their matching shRNA and the level of inhibition is 
comparable to the original situation of the wild-type virus 
with the wild-type shRNA. For the R4 escape mutant, in-
hibition is improved with the matching shRNA (white bar) 
compared  to  the  wild-type  shRNA  (grey  bar),  although 
inhibition is only partially restored. 
 
R6 is a special escape mutant because the single nucleo-
tide substitution imposes an altered RNA folding that oc-
cludes the target site (Westerhout et al, 2005). Therefore, 
RNAi is not rescued with the matching shRNA. For the R9 
mutant, the matching shRNA is not effective at all. These 
results show that it is possible to reconstitute at least some 
level of inhibition, and in most cases restore complete in-
hibition,  with  a  second  generation  of  shRNAs  aimed  at 
escape variants. 
 
We can apply this concept to the effective and conserved 
targets  of  HIV-1 listed in  Table 1. One can empirically 
determine which target site mutations result in replication 
competent escape variants by studying virus escape in cell 
culture  infections.  For  the  targets  with  a  conserved  se-
quence, we assume that most point mutations will affect 
virus replication. A conserved sequence may have multiple 
functions,  e.g.,  multiple  overlapping  reading  frames  and 
RNA or DNA signals that code for splicing, packaging or 
promoter functions. Because it is likely that multiple muta-
tions in the target sequence will result in impairment of its 
function(s), a first assumption is that only a single point 
mutation  is  allowed.  A  second  assumption  is  that  only 
silent  codon  changes  can  occur.  For  example,  the  con-
served tat/rev sequence (Surabhi and Gaynor,  2002) en-
codes two overlapping reading frames (Figure 3).  There 
are  9  silent  codon  changes  possible  for  each  individual 
open reading frame, but only at position 7 and 19 these 
changes are silent in both reading frames (Figure 3). In 
both cases, a silent variation at the first nucleotide position 
of  an  Arginine  (R)  codon  in  tat  coincides with  a  silent 
change of a third nucleotide of a rev codon. A combination 
of  three  shRNAs  targeting  the  wt,  A7C  and  A19C  se-
quences may prevent viral escape.  
 
In general, this strategy may be applied to all conserved 
HIV-1 targets. It is important to note that the success of 
this approach depends upon several criteria. First, only a 
limited number of escape routes should be possible, oth-
erwise too  many  second  generation shRNAs have to be 
designed. Second, the new shRNA should be capable of 
inducing RNAi. For instance, shNEF-wt partially inhibits 
the  escape  mutant  LAI-R9  but  the  adapted  shNEF-R9 
failed to silence LAI-R9 at all, indicating that this particu-
lar shRNA is inactive (Figure 2C). Finally, the target site 
should remain accessible (Westerhout et al, 2005; Schu-
bert et al, 2005b). The R6 escape variant provides an ex-
ample  where  any  shRNA is  likely  to  be  ineffective  be-
cause this nucleotide substitution induced a change of the 
RNA structure such that the target sequence is inaccessible 
(Westerhout et al, 2005). 
 
Anti-AIDS gene therapy 
For an effective therapy, the RNAi-triggering genes have 
to be transferred into the appropriate cells. Such a gene 
therapy protocol seems ideally suited for the treatment of 
individuals that are chronically infected with HIV-1 and 
fail on standard antiretroviral therapy. In chronically in-
fected individuals, HIV-1 infects a significant fraction of 
the mature T cells each day, leading to cell killing directly 
by HIV-1 or indirectly by the HIV-induced immune sys-
tem.  In  addition,  HIV-1  infection  may  induce  immune 
activation  resulting  in  apoptosis  in  uninfected  bystander 
cells (Herbein et al, 1998). Nevertheless, the preferential 
survival of even a minority of shRNA-expressing cells will 
result in their outgrowth over time. One could carry out an 
ex vivo gene therapy treatment of either the patients ma-
ture CD4+ T cells from the blood or CD34+ haematopoi-
etic stem cells from the bone marrow, and give them back 
to the patient. The stem cells will proliferate into mature T   
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Table 1. A list of published siRNA/shRNAs that inhibit HIV-1 
 
 
Target Gene 
 
 
ORF
a 
 
Position
b 
 
Target Sequence 
 
%
c 
 
Method
d 
 
Reference 
LTR 5’/3’, nef  1  130  GATGGTGCTTCAAGCTAGTAC  7
  A  Capodici 2002 
LTR 5’/3’, nef  1  293  GGCCCGAGAGCTGCATCCGG  6
  A  Suzuki 2005 
LTR 5’/3’, nef  1  324  GACTGCTGACATCGAGCTT  1
  A  Suzuki 2005 
LTR 5’/3’  0  350  GGGACUUUCCGCUGGGGAC  7
  A  Suzuki 2005 
LTR 5’/3’  0  468  AGACCAGATCTGAGCCTGG  6
  A  Jacque 2002 
LTR 5’/3’  0  597  GCCCTATCCCTTTACGTCA  0
  A  Surabhi 2002 
PBS  0  634  GGTGGCGCCCGAACAGGGACC  34  A,E  Han 2004 
gag, p17  1  896  GGGCAAGCAGGGAGCTAGAAC  23  A  Capodici 2002, Han2004 
gag, p24  1  1475  GAGAACCAAGGGGAAGTGACA  60  A  Capodici 2002 
gag, p24  1  1795  GCATTGGGACCAGGAGCGA  0  A  Hu 2002 
gag, p24  1  1822  GAAATGATGACAGCATGTC  62  D,E  Chang 2005 
gag, p7  1  2062  GATTGTACTGAGAGACAGGC  10  A,E  Novina 2002, Song 2003, 
Lee 2005 
gag, p7  1  2066  GTACTGAGAGACAGGCTAA  14  D  Pusch 2003 
pol, protease  1  2315  AGCTCTATTAGATACAGGA   44  D  Paul 2003, Scherer 2004 
pol, RT  1  2961  GAGACACCAGGGATTAGAT  21  A  Surabhi 2002 
pol, RNase  1  4168  GGAATTGGAGGAAATGAAC  49  D,E  Chang 2005 
pol, integrase  1  4960  GGTGAAGGGGCAGTAGTAA  68  D,E  Chang 2005 
pol, Integrase  1  4968  GGGGCAGTAGTAATACAAG  48  A  Hu 2002 
vif  1  5138  GGAAAGCTAAGGACTGGTT   0  A,E  Jacque 2002, Joshi 
2005 
vif  1  5195  GTTCAGAAGTACACATCCC  60  A,E  Lee 2005 
vif  1  5323  AGCACACAAGTAGACCCTG  26  A,D  Jacque 2002, Ni-
shitsuji 2004 
vif  1  5481  CTTGGCACTAGCAGCATTA  5  A  Jacque 2002 
Tat  1  5889  CTGCTTGTACCAATTGCTA  5  A,E,D  Boden 2003a/b & 2004b, 
Coburn 2002 
tat  1  5917  GTGTTGCTTTCATTGCCAA  6  E,D  Lee 2003 
tat  1  5952  CTAGAGCCCTGGAAGCATC  10  A  Surabhi 2002 
tat, rev  2  5969  TATGGCAGGAAGAAGCGGA  82  A  Surabhi 2002 
tat, Rev  2  5980  GAAGCGGAGACAGCGACGA  43  A  Surabhi 2002 
tat, rev  2  5983  GCGGAGACAGCGACGAAGAGC  18  B,C,E  Lee 2002, Li 2003, Scherer 
2004, Joshi 2005 
tat, rev  2  5994  GACGAAGAGCTCATCAGAACA  0  D  Boden 2004a 
vpu  1  6207  GAGCAGAAGACAGTGGCAA  55  D,E  Chang 2005 
vpu, env  2  6215  GACAGTGGCAATGAGAGTG  51  D,E  Chang 2005 
env  1  7154  GAGGGGACCAGGGAGAGCAC   0  A  Park 2003 
env  1  7370  GTTCTACTGTAATTCAACAC  0  A  Park 2003 
env  1  7466  GACACTCCCATGCAGAATAC  0  A  Park 2003 
env  1  7499  GATGTGGCAGGAAGTAGGAC  2  A  Park 2003 
rev, env  2  8474  CGGATCCTTAGCACTTATC  0  A  Coburn 2002 
rev, env  2  8483  GGCACTTATCTGGGACGAT  0  E  Lee 2005 
rev, env  2  8509  GCCTGTGCCTCTTCAGCTACC  60  B,C,E  Lee 2002, Li 2003, Scherer 
2004, Unwalla 2004, 
Banerjea 2003, Joshi 2005 
env  1  8761  GAATAAGACAGGGCTTGGA  11  A  Dave 2004 
env  1  8764  TAAGACAGGGCTTGGAAAG   11  A  Dave 2004 
nef  1  8960  GTGCCTGGCTAGAAGCACA  18  A,E  Jacque 2002, Das 2004 
nef  1  9071  AAGAAAAGGGGGGACTGGA  88  A  Dave 2004 
 
a number of open reading frames targeted 
b position in prototype HIV-1 strain HXB2 
c entries in Los Alamos full genome database (n=538) with 100% identity. In case a target sequence consists of more than 19 nucleotides, the percent-
age for each possible 19 nucleotide target sequence was calculated and the highest percentage is shown. 
d different methods of RNAi application were used to inhibit HIV-1: siRNA transfection (A), transient (B) and stable (C)  siRNA expression, transient 
(D) and stable (E) shRNA expression 
 
cells and move to the periphery, thus forming a constant 
supply of cells that resist HIV-1 infection. This means that 
even a relatively inefficient ex vivo gene therapy protocol 
may be beneficial through partial reconstitution of the im-
mune system.  
 
Viral vectors based on HIV-1, the lentiviral vectors, are 
superior over retroviral vectors for transduction of either T 
cells or haematopoietic stem cells. These vectors are pref-
erable candidates for gene therapy development for treat-
ment  of  HIV-1  infected  patients  (Strayer  et  al,  2005). 
However, the introduction of shRNAs against highly con-
served HIV-1 sequences may pose a problem for vector 
production,  since  these  shRNAs  could  cross-react  with 
critical  sequences  of  the  vector.  Indeed,  it  has  been  re-
ported  that expression  of shRNAs  that target  the  vector 
can result in a reduction of the titer (Banerjea et al, 2003; 
Chang et al, 2005).  One  may  expect that when a multiple   
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Figure 2. Counteracting HIV-1 escape with a second generation of shRNAs. (A) Hairpin structure of the shRNA molecules. Shown 
is the shNEF-wt and a second generation of shRNA variants that counteract escape mutants of HIV-1. Altered nucleotides are high-
lighted. (B) Molecular clones with sequence variation in the target were co-transfected with shRNA expressing constructs: either the 
shLUC control, the shNEF-wt or the matching shRNA variant. The number of basepair complementarity of the predicted siRNA and 
the target are shown. (C) Co-transfections were performed in 293T cells with 500 ng of pLAI molecular clone, 100 ng of pSUPER 
plasmid and 2.5 ng pRL as an internal control. Transfection was performed on 1.5 x 10
5 cells with lipofectamine-2000 according to 
the manufacturers instructions (Invitrogen). Two days post-transfection, CA-p24 was measured in the cell culture supernatant and 
Renilla activity measured in cell extract. The ratio between CA-p24 and internal control values yields the relative CA-p24 produc-
tion, for all pLAI transfections the control shLUC were set at 100%. Black bars represent co-transfections with the control shLUC, 
transfections with shNEF-wt are shown in grey. The white bars represent co-transfections of the respective pLAI molecular clones 
with the matching pSUPER-shRNA counterpart. 
 
 
shRNA expression lentiviral vector is developed, this will 
become  a  serious  issue,  but  solutions  for  this  potential 
problem are already available. With safety in mind, lenti-
viral  packaging  plasmids  were  developed  that  are  opti-
mized for human codon usage (Kotsopoulou et al, 2000; 
Wagner  et  al,  2000),  and  thus  quite  different  from  the 
original viral sequences. We found that the reduction in 
titer will be resolved when these constructs are used for 
lentiviral vector production (Ter Brake and Berkhout, in 
preparation).  
 
Interferon response 
The paradigm was that only dsRNAs larger than 30 base-
pairs induce the interferon response, but it was recently 
shown this is also true for some siRNAs. This effect is 
largely  dose-dependent  and may be specific for synthetic  
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wt - GUGCCUGGCUAGAAGCACA NA 19
R3 U10G GUGCCUGGCGAGAAGCACA NA 18 19
R3' G3A, U10G GUACCUGGCGAGAAGCACA NA 17 19
R4 G1C, C5U CUGCUUGGCUAGAAGCACA NA 17 19
R6 A14G GUGCCUGGCUAGAGGCACA NA 18 19
R9 9CA GUGCCUGGAUAGAAGCACA NA 18 19
pSUPER construct
pLAI clone mutation target sequence shLUC shNEF-wt shNEF-R3 shNEF-R3' shNEF-R4 shNEF-R6 shNEF-R9
wt - GUGCCUGGCUAGAAGCACA NA 19
R3 U10G GUGCCUGGCGAGAAGCACA NA 18 19
R3' G3A, U10G GUACCUGGCGAGAAGCACA NA 17 19
R4 G1C, C5U CUGCUUGGCUAGAAGCACA NA 17 19
R6 A14G GUGCCUGGCUAGAGGCACA NA 18 19
R9 9CA GUGCCUGGAUAGAAGCACA NA 18 19 
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Figure 3. Predicting viral escape. The highly conserved tat/rev target is shown with flanking sequences. The 19 nucleotide target 
sequence encompasses two overlapping reading frames for tat and rev. For each reading frame the codons and amino acid sequence 
are shown. Numerous silent codon changes are possible in each reading frame (grey box), but a silent mutation in both reading 
frames is possible only at 2 positions within the target sequence (black box). 
 
 
siRNAs (Myers et al, 2003; Kim et al, 2004). In addition, 
for systemic delivery of siRNAs in vivo, a sequence motif 
that interacts with a Toll like receptor was implicated in 
the induction of interferon (Hornung et al, 2005). How-
ever,  these  kind  of  interferon  responses  were  associated 
with  extracellularly  added  siRNAs  and  not  intracellular 
siRNAs when tested in peripheral blood mononuclear cells 
in  vitro  (Sioud,  2005).  We  propose to induce  RNAi  by 
intracellular shRNA expression and, therefore, we expect 
that these undesired responses will not occur. 
 
Since siRNA transfections clearly differ from intracellular 
shRNA expression, results obtained in siRNA experiments 
may  not  be  relevant  for  our  proposed  therapeutic  ap-
proach. Two shRNAs expressed from a lentiviral vector at 
a  relatively  high  multiplicity  of  infection  (moi)  did  not 
induce  the  interferon  response  (Anderson  and  Akkina, 
2005). However, the presence of an AA-dinucleotide near 
the transcription start site of an shRNA was implicated in 
interferon  induction  (Bridge  et  al,  2003;  Pebernard  and 
Iggo,  2004).  Interestingly,  such  a  shRNA  was  a  more 
prominent  inducer  when  expressed  from  a  U6  promoter 
compared to expression from an H1 promoter (Bridge et 
al, 2003). These experiments used an moi of 10, and the 
observed interferon response for these shRNAs was lost 
when an moi of 1 was used. More importantly, the major-
ity of shRNAs did not induce an interferon response even 
at the high moi. Few of the published anti-HIV siRNAs 
and shRNAs (Table 1) contain an AA-dinucleotide near 
the transcription start site, and none contain the motif that 
interacts with the Toll like receptor. We propose that the 
multiplicity of infection should always be kept below 1 in 
a therapeutic setting. This will keep expression levels low, 
thereby  preventing  possible  side  effects such  as transla-
tional  inhibition  or  saturation  of  the  miRNA  or  siRNA 
machinery  because  these  effects  are  usually  associated 
with a high concentration of siRNA molecules (Scacheri et 
al, 2004; Huppi et al, 2005). Anyhow, with at least nine 
candidate RNAi molecules available for the multi-shRNA 
approach, one could test for putative side effects and select 
non-toxic shRNAs for a clinical trial. 
 
Lentiviral vector design for multiple shRNA expression 
An important step towards anti-HIV RNAi therapy is the 
design  of  a  lentiviral  vector  that  expresses  multiple 
shRNAs. The goal is to achieve equal expression of each 
individual shRNA from the multiple shRNA vector, result-
ing in similar levels of inhibition per shRNA as compared 
to single shRNA constructs. In case the absolute inhibition 
would  decrease  for  individual  shRNAs  in  the  multiple 
shRNA vector, selective pressure would be lost, and ther-
apy would likely fail. 
 
An obvious way to construct a multiple shRNA vector is 
to clone different expression cassettes with the same pro-
moter in tandem orientation (Gonzalez et al, 2005). In the 
lentiviral  vector  context,  this  may  present  problems  be-
cause recombination may result in deletion of one or mul-
tiple  repeats  and  the  intervening  sequence  (An  and 
Telesnitsky, 2001; Marzio et al, 2001). A solution to this 
problem would be to increase the number of viral vector 
copies per cell, thereby ensuring the presence of at least 
one intact copy. However, this may be undesirable because 
the concentration of shRNAs will increase and introduce 
the risk of undesirable side effects. In addition, there will 
be an increased chance of insertion-induced oncogenesis 
and a significant increase in treatment cost. 
 
To avoid recombination within the lentiviral vector, one 
could use different promoters for shRNA expression. Nine 
different promoters have been used to drive the expression 
of shRNAs, most common are the  RNA polymerase  III 
promoters U6 (Yu et al, 2002) and H1 (Brummelkamp et 
al, 2002), which have been  routinely  used in HIV-1 re-
search (Paul et al, 2003; Boden et al, 2003a; Scherer et al, 
2004; Das et al, 2004; Boden et al, 2004a; Lee et al, 2005; 
rev codons 
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Chang et al, 2005). Alternatives include the RNA poly-
merase II promoter for the U1 snRNA gene (Denti et al, 
2004),  the  tRNA  Val  promoter  (Kawasaki  and  Taira, 
2003), the RNA polymerase I promoter (McCown et al, 
2003),  the  polymerase  II  cytomegalovirus  (CMV)  pro-
moter (Boden et al, 2003b; Song et al, 2004), the modified 
human tRNA Met promoter (Boden et al, 2003b), the VA I 
Adenovirus promoter  (Cordelier et al, 2003) and the 7S K 
promoter (Koper-Emde et al, 2004). A direct comparison 
of each of these promoters in the lentiviral vector context 
will provide the information to decide which ones to com-
bine in a multiple-shRNA viral vector.  
 
Another interesting option to avoid promoter duplication 
would be to express multiple siRNAs from one expression 
unit as a single transcript. Two shRNAs connected with a 
short linker sequence can be equally effective as individual 
shRNAs  (Anderson  et  al,  2003).  In  addition,  it  may  be 
possible to stack functional siRNAs on top of each other, 
with or without bulges in between. These transcripts could 
be designed resembling to mimic the branched microRNA 
precursors (Boden et al,  2004b). However, one  must  be 
aware  that  such  complex  RNA  structures  may  result  in 
significant  problems  within  the  context  of  the  lentiviral 
vector RNA genome. Approaches like these are still in the 
early development phase, but could eventually lead to an 
effective approach for multiple siRNA expression.  
 
When first generation shRNAs are combined with second 
generation shRNAs in the vector design, a shRNA repeat 
sequence will be present. However, the second generation 
shRNA differs in at least one basepair from the first gen-
eration and can be modified by introducing G-U wobble 
basepairs and a different loop sequence (Miyagishi et al, 
2004). These modifications can limit the repeat sequence 
to 19 nucleotides, which contains at least one point muta-
tion. We anticipate that such a minimal and imperfect re-
peat will not be problematic. 
 
CONCLUSIONS 
 
We  have  reviewed  current  publications  involving  RNAi 
approaches using siRNAs or shRNAs against the HIV-1 
genome. Since it is known that the application of individ-
ual shRNAs can lead to viral escape, the focus of this re-
view is on the development of a durable gene therapy that 
prevents viral escape. We worked out two strategies that 
may be employed. First, like many have suggested previ-
ously, multiple shRNAs targeting highly conserved HIV-1 
sequences can be combined. This will increase inhibition, 
and reduce the chances of escape exponentially with each 
added  shRNA.  Second,  we  introduce  a  new  strategy  to 
counteract viral escape. When highly conserved sequences 
are targeted, escape options are limited. If, in addition to 
the  wild-type  shRNA,  a  selection  of  second-generation 
shRNAs  would  be  included  that  anticipate  these  routes, 
escape may be prevented. As a proof of concept, we dem-
onstrate that it is possible to efficiently inhibit escape mu-
tants with such a second generation of shRNAs.  
 
Which shRNAs should than be used for an RNAi based 
gene therapy? The incoming HIV-1 RNA genome repre-
sents an efficient target and viral messengers are likely to 
be subject to RNAi in the nucleus and cytoplasm. There-
fore,  we  argued  that  target  site  selection  can  be  based 
solely  on conservedness among the different HIV-1 iso-
lates. From all published target sequences from the HIV-1 
genome, nine are conserved in at least half of all isolates. 
These seem the best candidates for a gene therapy based 
on multiple RNAi molecules. Studying escape for individ-
ual shRNAs in viral infection cultures will reveal whether 
second-generation shRNAs should be included. We expect 
that risks of interferon induction or other side effects like 
off-target inhibition or saturation of the miRNA machinery 
can be avoided in a gene therapy setting when the dosage 
of  vector  is  kept  low.  Nevertheless,  individual  shRNAs 
and any combination of shRNAs should be tested for these 
putative side effects. 
 
Recently,  Sirna  Therapeutics  reported  interim  data  for 
phase I clinical trials for treatment of age-related macular 
degeneration (Quinlan, 2005). No adverse or toxic effects 
were  observed  and  disease  stabilized  in  all  patients.  In 
addition, the first clinical trial involving lentiviral vectors 
showed no adverse effects in five patients (Manilla et al, 
2005). Combined, these results pave the way for a clinical 
trial involving RNAi and lentiviral vectors. Indeed, John 
Rossi of the City of Hope Beckman Research Institute in 
California  in collaboration  with  the Australian  company 
Benitec Limited are planning a clinical trial involving a 
multi-RNA  lentiviral  vector  approach  in  HIV-1  infected 
patients (Check, 2005). Their vector encodes a TAR de-
coy, a ribozyme against CCR5 and also a single shRNA 
against the HIV-1 genome (Li et al, 2003; Akkina et al, 
2003; Li et al, 2005). The outline we presented here may 
form the basis for the development of the next phase in 
RNAi-based treatments of HIV-1 infection. 
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